{"issuance_frequency":"","notes_translated":{"fr":"Le Relevé des maladies transmissibles au Canada est une publication bilingue et libre d'accès revue par un comité de lecture portant sur la prévention et le contrôle des maladies infectieuses nouvelles et tenaces.","en":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"P1M","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","metadata_created":"2020-06-01T18:00:54.673787","subject":["health_and_safety"],"date_modified":"2020-05-26 00:00:00","pspc_identification_number":"","metadata_modified":"2020-06-01T20:30:46.300522","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2020-06-01","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["COVID-19","pratiques exemplaires","Canada","tests","surveillance","point de soins","tests sérologiques","Canada","anticorps contre le SRAS-CoV-2","jeunes","enfants","maladie de Lyme","sérologie","sérologie à deux volets standard","essais immunoenzymatiques","tests d’immuno-empreinte","diagnostics","Comité consultatif national de l’immunisation","CCNI","influenza","grippe","vaccin antigrippal","conseils","VIH","hépatite C","utilisateurs de drogues injectables","consommation de drogues","comportements d’injection","pratiques sexuelles à risque","surdose","statut infectieux","dépistage","soins et traitement","coronavirus","Ontario","dépistage","vaccination","acceptation de la vaccination","résilience","confiance","stratégies fondées sur des données probantes"],"en":["COVID-19","best practices","Canada","testing","surveillance","point-of-care","serology testing","Canada","antibodies to SARS-CoV-2","youth","children","Lyme disease","serology","standard two-tiered testing","enzyme immunoassays","immunoblots","diagnostics","National Advisory Committee on Immunization","NACI","influenza","influenza vaccine","guidance","HIV","hepatitis C","people who inject drugs","drug use","injecting behaviours","sexual risk practices","overdose","infection status","testing","care and treatment","coronavirus","Ontario","testing","vaccination","vaccine acceptance","resiliency","confidence","evidence-based strategies"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"RMTC : Volume 46–5 - mai 2020 : Surveillance de l’infection nosocomiale","en":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c7c08cde-6c2b-4ab5-9536-baf9b390b40d","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–5 - mai 2020 : Surveillance de l’infection nosocomiale","en":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance","language":["en"],"created":"2020-06-01T18:00:54.841401","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr.html","last_modified":null,"position":0,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"314cadf1-3f5b-437e-af1d-df1973042049","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–5 - mai 2020 : Surveillance de l’infection nosocomiale","en":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance","language":["fr"],"created":"2020-06-01T18:00:54.841407","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc.html","last_modified":null,"position":1,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0373f4e3-6724-48aa-8244-079e52e17fe4","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–5 - mai 2020 : Surveillance de l’infection nosocomiale","en":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance","language":["en"],"created":"2020-06-01T18:00:54.841410","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05-eng.pdf","last_modified":null,"position":2,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"559f4c75-1d3b-4f1c-be4c-4c942d6a5e08","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–5 - mai 2020 : Surveillance de l’infection nosocomiale","en":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance","language":["fr"],"created":"2020-06-01T18:00:54.841412","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05f-fra.pdf","last_modified":null,"position":3,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ed8ed4cd-a84c-41cb-8765-7bafe5b4491d","related_relationship":"","name_translated":{"fr":"Les infections associées aux soins de santé et la résistance aux antimicrobiens dans les hôpitaux canadiens de soins de courte durée, 2014 à 2018 ","en":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018 ","language":["en"],"created":"2020-06-01T18:00:54.841413","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/amr-canadian-acute-care-hospitals-2014-2018.html","last_modified":null,"position":4,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c57460a4-898e-46ea-83cd-30088ca26681","related_relationship":"","name_translated":{"fr":"Les infections associées aux soins de santé et la résistance aux antimicrobiens dans les hôpitaux canadiens de soins de courte durée, 2014 à 2018","en":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018","language":["fr"],"created":"2020-06-01T18:00:54.841415","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/ram-hopitaux-canadiens-soins-actifs-2014-2018.html","last_modified":null,"position":5,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6ff6df3b-4bf4-4440-8fdb-bc1d4a9bb97b","related_relationship":"","name_translated":{"fr":"Les infections associées aux soins de santé et la résistance aux antimicrobiens dans les hôpitaux canadiens de soins de courte durée, 2014 à 2018","en":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018","language":["en"],"created":"2020-06-01T18:00:54.841417","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a01-eng.pdf","last_modified":null,"position":6,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9d6a059b-78ba-469a-93dc-5df66f9a1086","related_relationship":"","name_translated":{"fr":"Les infections associées aux soins de santé et la résistance aux antimicrobiens dans les hôpitaux canadiens de soins de courte durée, 2014 à 2018","en":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018","language":["fr"],"created":"2020-06-01T18:00:54.841419","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a01f-fra.pdf","last_modified":null,"position":7,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"25b6a332-30a1-40f6-95e9-97977c598c50","related_relationship":"","name_translated":{"fr":"Pratiques exemplaires du Réseau des laboratoires de santé publique du Canada relativement à la COVID-19 ","en":"Canadian Public Health Laboratory Network Best Practices for COVID-19"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Best Practices for COVID-19","language":["en"],"created":"2020-06-01T18:00:54.841421","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/covid-19-health-professional-cphln.html","last_modified":null,"position":8,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"76c499e8-4828-4bcd-ad0f-10823d39902e","related_relationship":"","name_translated":{"fr":"Pratiques exemplaires du Réseau des laboratoires de santé publique du Canada relativement à la COVID-19","en":"Canadian Public Health Laboratory Network Best Practices for COVID-19"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Best Practices for COVID-19","language":["fr"],"created":"2020-06-01T18:00:54.841423","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/covid-19-professionnel-sante-rlspc.html","last_modified":null,"position":9,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"50c7ea26-d402-45d1-8e1f-508e49f4bcb4","related_relationship":"","name_translated":{"fr":"Pratiques exemplaires du Réseau des laboratoires de santé publique du Canada relativement à la COVID-19","en":"Canadian Public Health Laboratory Network Best Practices for COVID-19"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Best Practices for COVID-19","language":["en"],"created":"2020-06-01T18:00:54.841425","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a02-eng.pdf","last_modified":null,"position":10,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ff7fd8fa-1a16-4a9f-b655-3f6fe626b72c","related_relationship":"","name_translated":{"fr":"Pratiques exemplaires du Réseau des laboratoires de santé publique du Canada relativement à la COVID-19","en":"Canadian Public Health Laboratory Network Best Practices for COVID-19"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Best Practices for COVID-19","language":["fr"],"created":"2020-06-01T18:00:54.841426","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a02f-fra.pdf","last_modified":null,"position":11,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e98db7a3-9ce5-4766-acb6-facf919f8851","related_relationship":"","name_translated":{"fr":"Énoncé du Réseau des laboratoires de santé publique du Canada sur les tests sérologiques au point de soins dans le cadre de la COVID-19","en":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19","language":["en"],"created":"2020-06-01T18:00:54.841428","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/point-care-serology-testing-covid-19.html","last_modified":null,"position":12,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"870cdd8c-f101-4edf-b074-6c920773a27f","related_relationship":"","name_translated":{"fr":"Énoncé du Réseau des laboratoires de santé publique du Canada sur les tests sérologiques au point de soins dans le cadre de la COVID-19","en":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19 ","language":["fr"],"created":"2020-06-01T18:00:54.841430","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/tests-serologiques-point-soins-cadre-covid-19.html","last_modified":null,"position":13,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8182eab0-e0bd-4cdc-b958-cf0708e5092b","related_relationship":"","name_translated":{"fr":"Énoncé du Réseau des laboratoires de santé publique du Canada sur les tests sérologiques au point de soins dans le cadre de la COVID-19","en":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19","language":["en"],"created":"2020-06-01T18:00:54.841432","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a03-eng.pdf","last_modified":null,"position":14,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"66f46897-415a-4a57-8938-b2dfc0d2e603","related_relationship":"","name_translated":{"fr":"Énoncé du Réseau des laboratoires de santé publique du Canada sur les tests sérologiques au point de soins dans le cadre de la COVID-19","en":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19","language":["fr"],"created":"2020-06-01T18:00:54.841434","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a03f-fra.pdf","last_modified":null,"position":15,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"fee695f6-ddbc-4db5-a2cc-921deb73859f","related_relationship":"","name_translated":{"fr":"Cas de COVID-19 confirmés en laboratoire chez les enfants et les jeunes au Canada, du 15 janvier au 27 avril 2020","en":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020","language":["en"],"created":"2020-06-01T18:00:54.841435","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/covid-19-children-youth-canada-january-april-2020.html","last_modified":null,"position":16,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"26b6c072-ff19-490d-86be-c7047f31581c","related_relationship":"","name_translated":{"fr":"Cas de COVID-19 confirmés en laboratoire chez les enfants et les jeunes au Canada, du 15 janvier au 27 avril 2020","en":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020","language":["fr"],"created":"2020-06-01T18:00:54.841437","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/covid-19-enfants-jeunes-canada-janvier-avril-2020.html","last_modified":null,"position":17,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"be5879e7-6dab-4f4e-8310-1131a375a9e0","related_relationship":"","name_translated":{"fr":"Cas de COVID-19 confirmés en laboratoire chez les enfants et les jeunes au Canada, du 15 janvier au 27 avril 2020","en":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020","language":["en"],"created":"2020-06-01T18:00:54.841439","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a04-eng.pdf","last_modified":null,"position":18,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"b10356a6-c817-4166-a573-ecc0a09b729e","related_relationship":"","name_translated":{"fr":"Cas de COVID-19 confirmés en laboratoire chez les enfants et les jeunes au Canada, du 15 janvier au 27 avril 2020","en":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory-confirmed COVID-19 in children and youth in Canada, January 15–April 27, 2020","language":["fr"],"created":"2020-06-01T18:00:54.841441","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a04f-fra.pdf","last_modified":null,"position":19,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"052561ff-45c0-466f-afd5-fe4e77a3bad8","related_relationship":"","name_translated":{"fr":"Algorithme de sérologie à deux volets modifiée pour le sérodiagnostic de la maladie de Lyme : contexte canadien","en":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context","language":["en"],"created":"2020-06-01T18:00:54.841443","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/diagnostic-algorithm-lyme-disease-canada.html","last_modified":null,"position":20,"revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"199865c2-111c-4f67-b5e3-f589f80fdaac","related_relationship":"","name_translated":{"fr":"Algorithme de sérologie à deux volets modifiée pour le sérodiagnostic de la maladie de Lyme : contexte canadien","en":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context","language":["fr"],"created":"2020-06-01T19:30:46.961024","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/algorithme-diagnostic-maladie-lyme-canada.html","last_modified":null,"position":21,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f97f6cd8-88c7-4eb0-bd8c-0d684d445bd4","related_relationship":"","name_translated":{"fr":"Algorithme de sérologie à deux volets modifiée pour le sérodiagnostic de la maladie de Lyme : contexte canadien","en":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context","language":["en"],"created":"2020-06-01T19:30:46.961030","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a05-eng.pdf","last_modified":null,"position":22,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5ba2e9c3-108c-4e90-991f-1f190d0b7214","related_relationship":"","name_translated":{"fr":"Algorithme de sérologie à deux volets modifiée pour le sérodiagnostic de la maladie de Lyme : contexte canadien","en":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context ","language":["fr"],"created":"2020-06-01T19:30:46.961032","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a05f-fra.pdf","last_modified":null,"position":23,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f3ebf5b2-6e95-44a2-80b9-d1e076c0c7d0","related_relationship":"","name_translated":{"fr":"Sommaire de la Déclaration du CCNI sur la vaccination antigrippale pour la saison 2020–2021","en":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021","language":["en"],"created":"2020-06-01T19:30:46.961034","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/naci-summary-influenza-2020-2021.html","last_modified":null,"position":24,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"46e2958c-59d0-42e4-9df0-4f1f23282bb9","related_relationship":"","name_translated":{"fr":"Sommaire de la Déclaration du CCNI sur la vaccination antigrippale pour la saison 2020–2021","en":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021 ","language":["fr"],"created":"2020-06-01T19:30:46.961036","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/sommaire-ccni-grippe-2020-2021.html","last_modified":null,"position":25,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"75746d3c-6794-4433-8e1c-ebc1238ba0fa","related_relationship":"","name_translated":{"fr":"Sommaire de la Déclaration du CCNI sur la vaccination antigrippale pour la saison 2020–2021","en":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021 "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021 ","language":["en"],"created":"2020-06-01T19:30:46.961038","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a06-eng.pdf","last_modified":null,"position":26,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"80af70da-6aeb-44d9-bd99-e0aaf40dc099","related_relationship":"","name_translated":{"fr":"Sommaire de la Déclaration du CCNI sur la vaccination antigrippale pour la saison 2020–2021","en":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021","language":["fr"],"created":"2020-06-01T19:30:46.961040","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a06f-fra.pdf","last_modified":null,"position":27,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"187d2619-303a-41e3-a005-b25366a67bfe","related_relationship":"","name_translated":{"fr":"Résultats nationaux de l’enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019","en":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019","language":["en"],"created":"2020-06-01T19:30:46.961056","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/survey-report-people-who-inject-drugs-canada-2017-2019.html","last_modified":null,"position":28,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"69885e03-a28e-40ba-8b5e-f9c50831b5d6","related_relationship":"","name_translated":{"fr":"Résultats nationaux de l’enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019","en":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019","language":["fr"],"created":"2020-06-01T19:30:46.961058","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/rapport-enquete-utilisateurs-drogues-injection-canada-2017-2019.html","last_modified":null,"position":29,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9cc90e5c-1fe5-4443-b04c-4370d2d6e3ee","related_relationship":"","name_translated":{"fr":"Résultats nationaux de l’enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019","en":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019","language":["en"],"created":"2020-06-01T19:30:46.961060","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a07-eng.pdf","last_modified":null,"position":30,"revision_id":"7289ffd4-f806-4ab0-b96e-faa0c3d72dca","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"d865e104-c3a2-4d2f-bab9-6a10d0b95484","related_relationship":"","name_translated":{"fr":"Résultats nationaux de l’enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019","en":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019","language":["fr"],"created":"2020-06-01T19:40:47.691014","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a07f-fra.pdf","last_modified":null,"position":31,"revision_id":"5c956413-9981-450c-9efd-2dcdb776f5d7","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"04bda620-b6de-4bb4-bf67-2c40ffdd872c","related_relationship":"","name_translated":{"fr":"Infographie sur les enquêtes Track au Canada","en":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019 ","language":["en"],"created":"2020-06-01T19:40:47.691019","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/infographic-tracks-survey-canada.html","last_modified":null,"position":32,"revision_id":"5c956413-9981-450c-9efd-2dcdb776f5d7","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"d0604fa3-9b0a-412c-80e8-501a7bbea55d","related_relationship":"","name_translated":{"fr":"Infographie sur les enquêtes Track au Canada","en":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019","language":["fr"],"created":"2020-06-01T19:40:47.691022","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/infographie-enquetes-track-canada.html","last_modified":null,"position":33,"revision_id":"5c956413-9981-450c-9efd-2dcdb776f5d7","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"12a06f37-3a0f-43a8-9a27-226afdd13952","related_relationship":"","name_translated":{"fr":"Infographie sur les enquêtes Track au Canada","en":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019","language":["en"],"created":"2020-06-01T19:50:49.667558","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a07a-eng.pdf","last_modified":null,"position":34,"revision_id":"3686cb60-f905-4fe8-a25a-0927fcced222","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f1dabfeb-ab2a-469b-b03e-12b8e1bc3be8","related_relationship":"","name_translated":{"fr":"Infographie sur les enquêtes Track au Canada","en":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Determinants of HIV and hepatitis C among people who inject drugs in Canada, 2017–2019","language":["fr"],"created":"2020-06-01T20:00:47.214887","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a07af-fra.pdf","last_modified":null,"position":35,"revision_id":"adfebf4c-9922-4a39-8054-3b869b5fcc85","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7afd38af-6a64-407d-8481-b135dd8b867a","related_relationship":"","name_translated":{"fr":"Données de surveillance de la COVID‑19 en Ontario, du 22 janvier au 22 février 2020","en":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020","language":["en"],"created":"2020-06-01T20:10:46.394254","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/covid-19-surveillance-data-ontario-january-22-february-22-2020.html","last_modified":null,"position":36,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"76c01e56-b996-41e5-8347-51c5d064cdf6","related_relationship":"","name_translated":{"fr":"Données de surveillance de la COVID‑19 en Ontario, du 22 janvier au 22 février 2020","en":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020","language":["fr"],"created":"2020-06-01T20:10:46.394259","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/donnees-surveillance-covid-19-ontario-22-janvier-22-fevrier-2020.html","last_modified":null,"position":37,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"435ed6d5-49c0-4481-9a55-9829fe099db9","related_relationship":"","name_translated":{"fr":"Données de surveillance de la COVID‑19 en Ontario, du 22 janvier au 22 février 2020 ","en":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020 "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020 ","language":["en"],"created":"2020-06-01T20:10:46.394261","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a08-eng.pdf","last_modified":null,"position":38,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1325dc74-b2c7-44dd-ab37-86fec34ec404","related_relationship":"","name_translated":{"fr":"Données de surveillance de la COVID‑19 en Ontario, du 22 janvier au 22 février 2020","en":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020 "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Surveillance of persons who tested negative for COVID-19 in Ontario, January 22–February 22, 2020 ","language":["fr"],"created":"2020-06-01T20:10:46.394263","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a08f-fra.pdf","last_modified":null,"position":39,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"bbf10373-1465-40af-8512-846aab7896d6","related_relationship":"","name_translated":{"fr":"Acceptation de la vaccination : comment instaurer et préserver la confiance dans la vaccination","en":"Vaccine acceptance: How to build and maintain trust in immunization"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine acceptance: How to build and maintain trust in immunization","language":["en"],"created":"2020-06-01T20:10:46.394265","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/canvax-building-trust-immunization.html","last_modified":null,"position":40,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"078f529c-51ef-4091-8346-2102c942fffa","related_relationship":"","name_translated":{"fr":"Acceptation de la vaccination : comment instaurer et préserver la confiance dans la vaccination","en":"Vaccine acceptance: How to build and maintain trust in immunization "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine acceptance: How to build and maintain trust in immunization ","language":["fr"],"created":"2020-06-01T20:10:46.394267","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-5-7-mai-2020/canvax-etablir-confiance-immunisation.html","last_modified":null,"position":41,"revision_id":"da094655-aca4-471b-98a5-451f36c57476","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"468ca360-4753-4a1f-a0b5-45e8dcb0a3d3","related_relationship":"","name_translated":{"fr":"Acceptation de la vaccination : comment instaurer et préserver la confiance dans la vaccination","en":"Vaccine acceptance: How to build and maintain trust in immunization "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine acceptance: How to build and maintain trust in immunization ","language":["en"],"created":"2020-06-01T20:30:46.363925","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a09-eng.pdf","last_modified":null,"position":42,"revision_id":"b1e3059a-d4a4-44c5-b79c-869799839655","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"2896423a-da2e-4f7d-9e47-a6968cb8c085","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e4cbd9b2-6580-4069-815a-3a23c6629f55","related_relationship":"","name_translated":{"fr":"Acceptation de la vaccination : comment instaurer et préserver la confiance dans la vaccination ","en":"Vaccine acceptance: How to build and maintain trust in immunization"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine acceptance: How to build and maintain trust in immunization","language":["fr"],"created":"2020-06-01T20:30:46.363930","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-5-may-7-2020/ccdrv46i05a09f-fra.pdf","last_modified":null,"position":43,"revision_id":"b1e3059a-d4a4-44c5-b79c-869799839655","resource_type":"website"}],"place_of_publication":[],"num_resources":44,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2020-05-07 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"2896423a-da2e-4f7d-9e47-a6968cb8c085","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"CCDR: Volume 46-5 -May 2020: Nosocomial infection surveillance","revision_id":"11716afb-1459-4592-a5a6-bd188bffe29b"}